托珠单抗
医学
置信区间
逻辑回归
内科学
不利影响
回顾性队列研究
改良兰金量表
优势比
儿科
疾病严重程度
脑病
相对风险
前瞻性队列研究
格林-巴利综合征
作者
Velda Xinying Han,Prithuja Poudyal,Vanessa Wan Mun Lee,Arushi Gahlot Saini,Shekeeb S. Mohammad,Sekhar C. Pillai,Gouri Rao Passi,Naveen Sankhyan,Ahmad Rithauddin Mohamed,Lokesh Lingappa,Hiroshi Sakuma,Russell Clive Dale,Ming Jin Lim,Terrence Gerard Sundram Thomas,for The International ANE Study Group
摘要
AIM: To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). METHOD: This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut-off for outcomes (binary good [mRS 0-2] vs poor [mRS 3-5]) according to day of tocilizumab administration, enabling a dichotomy of 'early' and 'late' treatment groups. Expected outcomes according to ANE severity score (ANE-SS) in early-treatment and late-treatment groups were compared against reference data (conventional therapy, no tocilizumab) for outcomes according to risk category (medium risk: ANE-SS score 2-4; high risk: ANE-SS score ≥5). RESULTS: From 2018 to 2023, 63 children (mean age 6 years 0 months [range: 8 months-15 years 4 months]; 33 males, 30 females) were treated with tocilizumab, alongside corticosteroids in all and intravenous immunoglobulin in 33 (52.4%). Logistic regression defined an optimal treatment window of ≤3.3 days. Compared to the reference data, early tocilizumab (≤ 72 hours after onset, n = 49) was associated with good outcomes in both high-risk (OR = 11.43, 95% confidence interval [CI] = 1.64-127.4, p = 0.01) and medium-risk (OR = 12.80, 95% CI = 2.15-67.8; p = 0.006) ANE-SS categories. No tocilizumab-related adverse events were reported. INTERPRETATION: Early tocilizumab treatment was associated with improved outcomes in severe ANE, with no adverse events, compared to conventional therapy alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI